Please use this identifier to cite or link to this item:
Title: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
Authors: Cassinello, J
Arranz, J Á
Piulats, J M
Sánchez, A
Pérez-Valderrama, B
Mellado, B
Climent, M Á
Olmos, D
Carles, J
Lázaro, M
Keywords: Abiraterone;Androgen deprivation treatment;Cabazitaxel;Castration-resistant prostate cancer;Docetaxel;Enzalutamide;Hormone-sensitive advanced prostate cancer;Radium 223
metadata.dc.subject.mesh: Antineoplastic Agents
Prostatic Neoplasms
Issue Date: 13-Nov-2017
Abstract: Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
metadata.dc.identifier.doi: 10.1007/s12094-017-1783-2
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5785604.pdf439,91 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons